radioimmunoimaging

Radioimmunoimaging (RII) is a method in which a specific antibody against a tumor-associated antigen is labeled with a radionuclide and injected into the human body, and the blood flows to the tumor tissue to bind to the tumor-associated antigen, thereby causing local radioactive concentration of the tumor tissue. Exceeding normal tissue, a positive imaging of the tumor was obtained using in vitro imaging techniques. Radionuclide-labeled antibodies against tumors and related antigens, used as biological missiles, are tumor-positive imaging agents, called tumor immuno-imaging diagnostic techniques. It is a new technology for localization diagnosis of ovarian cancer in recent years. Basic Information Specialist Category: Oncology Inspection Category: Radionuclide Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: The local radioactive concentration of tumor tissue exceeds that of normal tissues, and the in vitro imaging technique obtains a positive imaging of the tumor. Used to assist in the diagnosis of tumors. Tips: Please check the expedition to the undergraduate room on the same day. Some patients may require a laxative to clear the intestines before the imaging test. Normal value The blood supply state of the tumor tissue and the degree of exposure of the tumor antigen determine the concentration of the labeled antibody. The tumor with better blood supply has better localization effect. Clinical significance Abnormal results The local radioactive concentration of tumor tissue exceeded normal tissue, and the in vitro imaging technique obtained a positive imaging of the tumor. The population to be examined: the diagnosis of clinically assisted tumors. Mainly used for the diagnosis of colorectal cancer, primary liver cancer, ovarian cancer, lung cancer, prostate cancer, AFP secretory tumor, CEA related tumor, endodermal sinus tumor. Tumors that are misdiagnosed by other methods can be displayed for initial diagnosis and staging of cancer patients, which can determine where recurrence and spread occur. RII is a biochemical marker for detecting tumor cells, so it can be used as a deterministic test for growing and surviving tumors to screen patients who are suitable for labeling the same antibody with different nuclides for RIT (radioimmunotherapy). Positive results may be diseases: primary liver cancer, viral dermatitis considerations Forbidden before inspection: Please check the expedition to the undergraduate room on the same day. Some patients may require a laxative to clear the intestines before the imaging test. Requirements for examination: 10 minutes before the start of the tracer injection and after the injection, the patient should be at rest and use a sedative if necessary. Blood glucose should be monitored before the tracer is injected. Inspection process The specific antibody against tumor-associated antigen is labeled with radionuclide and injected into the human body, and the blood flows to the tumor tissue to bind to the tumor-associated antigen, so that the tumor tissue is locally concentrated and concentrated more than normal tissue, and then obtained by in vitro imaging technology. Positive imaging of the tumor. Not suitable for the crowd Inappropriate crowd: None. Adverse reactions and risks Nothing.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.